Heterologous Chimpanzee Adenoviral Vectors Are a Highly Immunogenic and Adaptable Viral Vector Platform
Human adenoviral vectors commonly used for vaccines are often limited by pre-existing anti-vector antibodies that can blunt vaccine-induced immune responses.1
Our ChiVax™ technology addresses this issue without sacrificing the immunological benefits of adenoviral-based vaccines.
*Black- 1:10 dilution; Grey- 1:40 dilution.
Our Platform Technologies Can Offer Enhanced and Superior CD8+ T Cell Responses Through Heterologous Chimpanzee Adenoviral Vectors* and Integrated Platforms
*Dr. Ertl pioneered this technology, which is currently in use to combat multiple human diseases, including COVID-19.
Benefits of Adenoviral Vectors
Superior CD8+ T cell responses
Greater potential for clinical success in cancer and other CD8+ T cell-driven disease states
Potential for widespread global use
- Improved affordability
- Convenient shipping and storage, daily preparation, and administration
- Scalable: 100s of millions of doses administered for COVID‑19 across different adenoviral vectors/programs
AdC, chimpanzee adenovirus serotype 68; AdC6/7, heterologous chimpanzee adenoviral viral vectors of serotype 6 or 7; AdHu, adenovirus human; CD, cluster of differentiation; gCPM, genetically encoded checkpoint modifier.
- Chen H, et al J Virol. 2010;84(20):10522–32.